BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34290908)

  • 41. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
    Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
    Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
    Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH
    J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
    Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
    Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
    Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
    Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
    [No Abstract]   [Full Text] [Related]  

  • 49. The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
    Gurin D; Slavik M; Hermanova M; Selingerova I; Kazda T; Hendrych M; Shatokhina T; Vesela M
    J Oral Pathol Med; 2020 Oct; 49(9):886-896. PubMed ID: 32516834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
    Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aligning digital CD8
    Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
    Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.
    Zhang S; Minaguchi T; Xu C; Qi N; Itagaki H; Shikama A; Tasaka N; Akiyama A; Sakurai M; Ochi H; Satoh T
    BMC Cancer; 2020 Feb; 20(1):127. PubMed ID: 32066405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
    Lopci E; Toschi L; Grizzi F; Rahal D; Olivari L; Castino GF; Marchetti S; Cortese N; Qehajaj D; Pistillo D; Alloisio M; Roncalli M; Allavena P; Santoro A; Marchesi F; Chiti A
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1954-61. PubMed ID: 27251642
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies.
    Stephan-Falkenau S; Streubel A; Mairinger T; Blum TG; Kollmeier J; Mairinger FD; Bauer T; Pfannschmidt J; Hollmann M; Wessolly M
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
    Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
    Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC.
    Li Y; Zhao X; Xiao H; Yang B; Liu J; Rao W; Dai X; Li M; Dai N; Yang Y; Wang D
    BMC Cancer; 2021 Mar; 21(1):233. PubMed ID: 33676448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.